With the goal of finding the best treatment strategies to circumvent or prevent the emergence of acquired resistance to anti-EGFR therapy in the clinical setting, several preclinical studies have been conducted in the last decades to characterize the molecular drivers of acquired resistance to anti-EGFR therapy in CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.